Skip to main content

Table 1 M1 vaccine expressing MC38 neoantigens (see Fig. 2)

From: Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth

   WT Peptide Neoantigen   
# Symbol Seq H2-Db H2-Kb Seq H2-Db H2-Kb DAI Imm.Resp.
1 Wbp7 SNFHFMCAR 39,828 499 SNFHFMCAL 7213 10 > 5 +
2 Hace1 QINAFLQGF 44,767 1128 QIYAFLQGF 37,598 39 > 5 +
3 Hdgfrp2 KGYPHWPAR 43,395 4131 KGYPHWPAL 12,706 33 > 5
4 Kpna6 CTLQFEAAW 34,408 1319 CTLQFEAAL 8030 42 > 5
5 Aurkaip1 RTRFLRRKV 45,504 6329 RTRFLRLKV 42,713 7062 1
6 Srebf2 HSFVDSVGF 33,887 3985 HSFVYSVGF 38,481 135 > 5
7 Mttp TGYVERSPR 41,635 11,661 TGYVERSPL 9548 131 > 5
8 Nle1 MALSTDYAL 1982 1278 MALSTYYAL 407 46 > 5 +/−
9 Zbtb24 SLLEHMSLH 43,119 18,788 SLLEHMSLL 7649 265 > 5
10 Hnrnpf GYVVKLRGL 42,720 3065 SYVVKLRGL 38,966 438 > 5
  1. Predicted binding are expressed as nM values according to NetMHC-4. Immunogenic neoantigens (+) and intermediate response (+/) are indicated. Bold residues in the peptide sequence are mutated